MARÍA
DE LAGARDE SEBASTIÁN
Profesora asociada de Ciencias de la Salud
Hospital Universitario La Paz
Madrid, EspañaPublikationen in Zusammenarbeit mit Forschern von Hospital Universitario La Paz (20)
2024
-
Transition times across the HIV care continuum in Spain from 2005 to 2022: a longitudinal cohort study
The Lancet HIV, Vol. 11, Núm. 7, pp. e470-e478
2023
-
Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens
The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 11, pp. 2696-2701
2022
-
Discovering HIV related information by means of association rules and machine learning
Scientific Reports, Vol. 12, Núm. 1
2021
-
Blood Bacterial Profiles Associated With Human Immunodeficiency Virus Infection and Immune Recovery
The Journal of infectious diseases, Vol. 223, Núm. 3, pp. 471-481
2019
-
Effects of immunonutrition in advanced human immunodeficiency virus disease: A randomized placebo-controlled clinical trial (Promaltia study)
Clinical Infectious Diseases, Vol. 68, Núm. 1, pp. 120-130
2018
-
Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients
Medicine (United States), Vol. 97, Núm. 38
-
Low-level viremia is associated with clinical progression in HIV-infected patients receiving antiretroviral treatment
Journal of Acquired Immune Deficiency Syndromes, Vol. 78, Núm. 3, pp. 329-337
-
Persistently altered liver test results in hepatitis C patients after sustained virological response with direct-acting antivirals
Journal of Viral Hepatitis, Vol. 25, Núm. 7, pp. 818-824
2017
-
Dual Therapy with Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy with Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial
Clinical Infectious Diseases, Vol. 65, Núm. 12, pp. 2112-2118
-
Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach
PLoS ONE, Vol. 12, Núm. 9
-
Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)
Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253
2016
-
Human immunodeficiency virus/hepatitis C virus coinfection in Spain: Prevalence and patient characteristics
Open Forum Infectious Diseases, Vol. 3, Núm. 2
-
Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013
Journal of Infection, Vol. 72, Núm. 5, pp. 587-596
-
MicroRNA profile in CD8+ T-lymphocytes from HIV-infected individuals: Relationship with antiviral immune response and disease progression
PLoS ONE, Vol. 11, Núm. 5
-
Toward a comprehensive care of HIV patients: finding a strategy to detect depression in a Spanish HIV cohort
AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, Vol. 28, Núm. 7, pp. 834-841
2015
-
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial
The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784
-
Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): A randomised, open-label, non-inferiority trial
The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 785-792
2014
-
A prospective cohort study of neurocognitive function in aviremic HIV-infected patients treated with 1 or 3 antiretrovirals
Clinical Infectious Diseases, Vol. 59, Núm. 11, pp. 1627-1634
-
Pattern of neurocognitive function in patients receiving boosted protease inhibitor monotherapy: A detailed neuropsychological study
Journal of NeuroVirology, Vol. 20, Núm. 4, pp. 362-370